Pathstone Family Office’s Halozyme HALO Stock Holding History

Pathstone Family Office’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$219K	Buy	+5,736	New	+$235K	﹤0.01%	1455
2022 Q4	–	Sell	-5,382	Closed	-$213K	–	1532
2022 Q3	$213K	Buy	5,382 +260	+5%	+$11.5K	﹤0.01%	1323
2022 Q2	$225K	Buy	+5,122	New	+$222K	0.01%	909
2022 Q1	–	Sell	-5,018	Closed	-$202K	–	995
2021 Q4	$202K	Sell	5,018 -69	-1%	-$2.58K	0.01%	838
2021 Q3	$207K	Buy	+5,087	New	+$213K	0.01%	807

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Pathstone Family Office's HALO Position: Q3 2023 in Review

Pathstone Family Office opened a new position in Halozyme (HALO) in Q3 2023: 5,736 shares worth $219K. The stake represents ﹤0.01% of the portfolio and ranks #1455 among its holdings. This is a return to the name: Pathstone Family Office previously reported a position in HALO as recently as Q3 2022.

Pathstone Family Office first reported a position in HALO in Q3 2021 and has held it in 5 quarters since. The position peaked at $225K in Q2 2022. 389 funds tracked by Wall St. Rank hold HALO as of Q3 2023.

Pathstone Family Office held 5,736 shares of Halozyme worth $219K as of Q3 2023.
Halozyme was a new Pathstone Family Office position in Q3 2023.
Halozyme made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1455 holding.
Pathstone Family Office first reported a position in Halozyme in Q3 2021 and has held it in 5 quarters since.
Pathstone Family Office's Halozyme position peaked at $225K in Q2 2022.
389 funds tracked by Wall St. Rank held Halozyme as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.